Lamivudina Farmoz

Lamivudine, the active ingredient in Lamivudina Farmoz, is a nucleoside reverse transcriptase inhibitor (NRTI) presented as an oral formulation for oral use. It is used to treat HIV-1 infection and chronic hepatitis B infection in appropriate patients. GNH USA supplies Lamivudina Farmoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamivudine is indicated for viral infections that involve reverse transcriptase activity. - HIV-1 infection: reduces viral load and helps maintain immune function when used in combination therapy. - Chronic hepatitis B infection: suppresses viral replication and improves liver function in infected individuals.

Lamivudine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal discomfort. - Headache: transient cranial pain. - Fatigue: general tiredness. - Diarrhea: loose stools. - Insomnia: difficulty sleeping.

Serious or Rare Side Effects: - Lactic acidosis: severe metabolic disturbance requiring immediate medical attention. - Hepatomegaly with steatosis: liver enlargement with fat accumulation. - Severe rash or hypersensitivity: skin reactions that may progress to systemic involvement. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain.

Lamivudina Farmoz should be used with consideration of the following precautions. - Renal function: assess kidney function before initiating therapy and monitor periodically. - Hepatic function: evaluate liver enzymes and monitor for signs of hepatic impairment. - Pregnancy: discuss potential risks and benefits with a healthcare professional before use. - Breastfeeding: consider infant exposure and consult a physician regarding continuation. - Drug resistance: avoid monotherapy to reduce the risk of viral resistance development. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Lamivudina Farmoz can interact with other medications, affecting efficacy or safety.

Major Interactions (Avoid): - Didanosine: concurrent use increases risk of severe peripheral neuropathy and pancreatitis. - Stavudine: combined therapy may enhance mitochondrial toxicity.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce lamivudine plasma concentrations, requiring monitoring. - Proton pump inhibitors: potential alteration of absorption, observe therapeutic response. - Anticoagulants (e.g., warfarin): may require INR monitoring due to possible interaction.